• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Schering plant fire spares contrast unit

Article

A fire this month at one of Schering's plants in Bergkamen, Germany,had no effect on the pharmaceutical company's contrast agent manufacturing,according to a Schering spokesperson. The fire broke out July16 at Plant B, which manufactures hormone

A fire this month at one of Schering's plants in Bergkamen, Germany,had no effect on the pharmaceutical company's contrast agent manufacturing,according to a Schering spokesperson. The fire broke out July16 at Plant B, which manufactures hormone products, and causedestimated damage of over DM 1 million ($674,000) before it wasextinguished. Schering's contrast manufacturing facility, PlantF, is in a separate building from the one in which the fire brokeout, according to the spokesperson.

In other Schering news, the company is expected to post strongerrevenues and income this year, according to Reuter SecuritiesReport. An analyst said the improvement is due to added revenuesfrom several acquisitions made last year, including that of contrastinjector firm Medrad. An improved exchange rate and the end ofextraordinary charges related to its withdrawal of Isovist 280from the market will also help Schering's bottom line. The analystestimated that Schering will report revenues for the year of DM5.7 billion ($3.83 billion), up 24%, and income of DM 337 million($227 million), up 35%.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.